Stock listing
Frankfurt:LYF EKF Diagnostics Holdings plc Aktie
German listing (Frankfurt) of EKF Diagnostics Holdings plc · home listing LSE:EKF
Follow EKF Diagnostics Holdings plc into a list and get an email when it puts out news.
Share price · FWB:LYF
€0.27 EUR +0.01 (+2.3%)
Close on Nov 20, 2026
- Day range
- €0.268 – €0.27 EURNov 20, 2026
- Market cap
- €115.6M EURAt the close on Nov 20, 2026 · price × 428.0M shares outstanding
- 52-week range
- €0.23 – €0.343 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:EKF · Home | 24.00p GBX (pence) | +0.60 (+2.6%) | 50,738 | 24.00p | 24.00p | 23.50p | 23.40p | Close on Nov 20, 2026 |
| Frankfurt:LYF | €0.27 EUR | +0.006 (+2.3%) | — | €0.268 | €0.27 | €0.268 | €0.264 | Close on Nov 20, 2026 |
| OTC:EKDHF | $0.329 USD | 0.000 (0.0%) | — | $0.329 | $0.329 | $0.329 | $0.329 | Close on Nov 6, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:LYF · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.277 | +0.011 | +4.1% | €0.286 | €0.287 | €0.276 | 0 | |
| €0.266 | +0.002 | +0.8% | €0.266 | €0.266 | €0.266 | 0 | |
| €0.264 | +0.002 | +0.8% | €0.264 | €0.264 | €0.264 | 0 | |
| €0.262 | -0.002 | -0.8% | €0.262 | €0.262 | €0.262 | 0 | |
| €0.264 | -0.007 | -2.6% | €0.272 | €0.272 | €0.263 | 0 | |
| €0.271 | +0.009 | +3.4% | €0.27 | €0.272 | €0.27 | 0 | |
| €0.262 | -0.013 | -4.7% | €0.262 | €0.262 | €0.262 | 0 | |
| €0.275 | -0.005 | -1.8% | €0.275 | €0.275 | €0.275 | 0 | |
| €0.28 | +0.007 | +2.6% | €0.28 | €0.28 | €0.28 | 0 | |
| €0.273 | -0.001 | -0.4% | €0.273 | €0.273 | €0.273 | 0 | |
| €0.274 | 0.00 | 0.0% | €0.274 | €0.274 | €0.274 | 0 | |
| €0.274 | -0.004 | -1.4% | €0.274 | €0.274 | €0.274 | 0 | |
| €0.278 | -0.002 | -0.7% | €0.278 | €0.278 | €0.278 | 0 | |
| €0.28 | -0.001 | -0.4% | €0.28 | €0.28 | €0.28 | 0 | |
| €0.281 | +0.004 | +1.4% | €0.281 | €0.281 | €0.281 | 0 | |
| €0.277 | +0.012 | +4.5% | €0.276 | €0.28 | €0.275 | 0 | |
| €0.265 | -0.018 | -6.4% | €0.265 | €0.265 | €0.265 | 0 | |
| €0.283 | -0.007 | -2.4% | €0.283 | €0.283 | €0.283 | 0 | |
| €0.29 | +0.002 | +0.7% | €0.29 | €0.29 | €0.29 | 0 | |
| €0.288 | +0.021 | +7.9% | €0.288 | €0.288 | €0.288 | 0 | |
| €0.267 | 0.00 | 0.0% | €0.267 | €0.267 | €0.267 | 0 | |
| €0.267 | +0.001 | +0.4% | €0.267 | €0.267 | €0.267 | 0 | |
| €0.266 | -0.002 | -0.7% | €0.266 | €0.266 | €0.266 | 0 | |
| €0.268 | -0.001 | -0.4% | €0.268 | €0.268 | €0.268 | 0 | |
| €0.269 | -0.003 | -1.1% | €0.271 | €0.272 | €0.268 | 0 | |
| €0.272 | +0.003 | +1.1% | €0.273 | €0.275 | €0.272 | 0 | |
| €0.269 | -0.007 | -2.5% | €0.269 | €0.269 | €0.269 | 0 | |
| €0.276 | +0.006 | +2.2% | €0.276 | €0.276 | €0.276 | 0 | |
| €0.27 | +0.001 | +0.4% | €0.27 | €0.27 | €0.27 | 0 | |
| €0.269 | +0.002 | +0.7% | €0.267 | €0.272 | €0.266 | 0 | |
| €0.267 | -0.018 | -6.3% | €0.286 | €0.303 | €0.266 | 734 | |
| €0.285 | +0.004 | +1.4% | €0.284 | €0.287 | €0.284 | 0 | |
| €0.281 | +0.006 | +2.2% | €0.273 | €0.281 | €0.272 | 0 | |
| €0.275 | +0.002 | +0.7% | €0.275 | €0.275 | €0.275 | 0 | |
| €0.273 | -0.013 | -4.5% | €0.286 | €0.288 | €0.272 | 0 | |
| €0.286 | +0.006 | +2.1% | €0.282 | €0.288 | €0.28 | 0 | |
| €0.28 | +0.004 | +1.4% | €0.277 | €0.282 | €0.274 | 0 | |
| €0.276 | -0.008 | -2.8% | €0.279 | €0.282 | €0.276 | 0 | |
| €0.284 | 0.00 | 0.0% | €0.285 | €0.287 | €0.283 | 0 | |
| €0.284 | +0.006 | +2.2% | €0.28 | €0.287 | €0.28 | 0 | |
| €0.278 | -0.002 | -0.7% | €0.278 | €0.278 | €0.278 | 0 | |
| €0.28 | +0.004 | +1.4% | €0.279 | €0.281 | €0.277 | 0 | |
| €0.276 | -0.002 | -0.7% | €0.275 | €0.276 | €0.275 | 0 | |
| €0.278 | +0.003 | +1.1% | €0.278 | €0.278 | €0.278 | 0 | |
| €0.275 | -0.003 | -1.1% | €0.275 | €0.276 | €0.275 | 0 | |
| €0.278 | -0.001 | -0.4% | €0.28 | €0.28 | €0.278 | 0 | |
| €0.279 | +0.005 | +1.8% | €0.279 | €0.279 | €0.279 | 0 | |
| €0.274 | -0.003 | -1.1% | €0.274 | €0.274 | €0.274 | 0 | |
| €0.277 | 0.00 | 0.0% | €0.277 | €0.277 | €0.277 | 0 | |
| €0.277 | -0.002 | -0.7% | €0.277 | €0.277 | €0.277 | 0 | |
| €0.279 | -0.003 | -1.1% | €0.28 | €0.28 | €0.278 | 0 | |
| €0.282 | +0.009 | +3.3% | €0.277 | €0.283 | €0.277 | 0 | |
| €0.273 | -0.007 | -2.5% | €0.273 | €0.273 | €0.273 | 0 | |
| €0.28 | -0.003 | -1.1% | €0.28 | €0.28 | €0.28 | 0 | |
| €0.283 | +0.006 | +2.2% | €0.283 | €0.283 | €0.283 | 0 | |
| €0.277 | 0.00 | 0.0% | €0.276 | €0.277 | €0.276 | 0 | |
| €0.277 | +0.006 | +2.2% | €0.277 | €0.277 | €0.277 | 0 |
- Ticker
- Frankfurt:LYF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Jul 30, 2026
H1 2026 Trading Update
Latest earnings call · Sep 15, 2026
EKF Diagnostics Holdings (LSE:EKF) — Interim results for the six months ended 30 June 2026
Replay and transcript
Latest deck · Sep 15, 2026
H1 2026 Earnings Presentation
Earnings · 31 slides
Latest news
H1 2026 Trading Update
Jul 30, 2026
Closed €0.287 (-1.0%) on Jul 30, 2026
Long Term Incentive Plan Award
May 20, 2026
Closed €0.304 (+5.2%) on May 21, 2026
AGM statement & positive Q1 trading update
May 19, 2026
Closed €0.338 (+16.2%) on May 19, 2026
Board Changes
Apr 27, 2026
Closed €0.276 (+0.7%) on Apr 27, 2026
Posting of Annual Report & Notice of AGM
Apr 24, 2026
Closed €0.276 (+0.7%) on Apr 27, 2026
Acquisition of assets from Beep Insights
Apr 13, 2026
Closed €0.26 (+0.4%) on Apr 13, 2026
Share Buyback
Apr 10, 2026
Closed €0.259 (-0.4%) on Apr 10, 2026
Full year results
Mar 24, 2026
Closed €0.265 (+0.4%) on Mar 24, 2026
Holding(s) in Company
Mar 19, 2026
Closed €0.265 (-1.1%) on Mar 19, 2026
Notice of Results
Mar 5, 2026
Closed €0.285 (-2.4%) on Mar 5, 2026
EKF Diagnostics Holdings plc on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 17 in the last 12 months · 283 in all · newest Jul 30, 2026 · oldest 2003
- Calls
- 13 calls with a replay · 13 with a transcript · latest Sep 15, 2026
- Decks
- 30 decks · latest Sep 15, 2026
Where EKF Diagnostics Holdings plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:EKF · Home listing | LSE | United Kingdom | GBX |
| Frankfurt:LYF · This page | Frankfurt | Germany | EUR |
| OTC:EKDHF | OTC | United States | USD |
| LS Exchange:622434 | LS Exchange | Germany | EUR |
| Lang & Schwarz:622434 | Lang & Schwarz | Germany | EUR |
| Aquis:EKFL | Aquis | United Kingdom | GBX |
| Stuttgart:LYF | Stuttgart | Germany | EUR |
| AQUIS:EKF.GB | AQUIS | United Kingdom | GBX |
| Turquoise:EKFL | Turquoise | United Kingdom | GBX |
Valuation
P/E 48.4× against a median of 13.4×: 5th lowest of 6 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £88.21M GBP
- P/E
- 48.4×
- EV/sales
- 1.7×
- EV/EBITDA
- 7.1×
- Price/book
- 1.5×
- Gross margin
- 51.3%
- Operating margin
- 13.5%
- Net margin
- 4.1%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| EKF Diagnostics Holdings plc · LSE:EKF | US$134.4M | US$115.4M | 48.4× | 1.7× | 7.1× | 1.5× | 4.1% | 0.0× | n/a |
| Boditech Med, Inc. · KRX:206640 | US$152.0M | US$120.9M | 7.9× | 0.9× | 4.4× | 0.8× | 14.8% | 0.0× | n/a |
| Genovis AB · OMXSTO:GENO | US$150.3M | US$142.9M | 74.9× | 10.8× | 41.7× | 5.0× | 15.1% | 0.3× | n/a |
| Genomictree, Inc. · KRX:228760 | US$147.7M | US$88.88M | n/a | 40.6× | n/a | 1.6× | −306.4% | 0.0× | n/a |
| Anbio Biotechnology · NASDAQ:NNNN | US$145.7M | US$133.8M | 22.8× | 15.5× | n/a | 4.8× | 74.1% | 0.0× | 0.56 |
| MaxCyte, Inc. · NASDAQ:MXCT | US$141.5M | US$57.06M | n/a | 1.7× | n/a | 0.9× | −81.4% | 0.1× | 0.93 |
| Shanghai Rightongene Biotechnology Co. Ltd. Class A · SSE:688217 | US$139.3M | US$102.6M | n/a | 4.6× | n/a | 1.1× | −43.9% | 0.0× | n/a |
| Bioventix PLC · LSE:BVXP | US$133.3M | US$126.3M | 13.4× | 7.4× | 9.7× | 9.2× | 57.8% | 0.0× | n/a |
| Curiosis, Inc. · KRX:494120 | US$131.1M | US$117.6M | n/a | 18.7× | n/a | 7.1× | −93.3% | 0.0× | n/a |
| Bioneer Corporation · KRX:064550 | US$127.6M | US$107.1M | n/a | 0.4× | 10.0× | 0.8× | −1.9% | 0.3× | n/a |
| Fine Foods & Pharmaceuticals N.T.M. SpA · MIL:FF | US$123.5M | US$174.6M | 11.1× | 0.6× | 4.6× | 0.8× | 4.0% | 0.6× | n/a |
| Median of the others | US$140.4M | US$119.3M | 13.4× | 6.0× | 9.7× | 1.4× | 1.0% | 0.0× | 0.75 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 34.67 GBX · Analysts' mean
- EPS, year to Dec 2026
- 0.017 · 3 analysts
- Revenue, year to Dec 2026
- 54.56M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Gavin Jones | Chief Executive Officer |
| Helen Jones | Chief Financial Officer |
| Julian Baines | Executive Chairman |
Board
| Director | Role |
|---|---|
| Julian Baines | Executive Chairman |
| Christian Rigg | Senior Independent Non-Executive Director |
| Christopher Mills | Non-Executive Director |
| Gavin Jones | Chief Executive Officer |
| Helen Jones | Chief Financial Officer |
| Jenny Winter | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| EKF Diagnostics Holdings (LSE:EKF) Q2 2026 Earnings Call | Tue, Sep 15, 2026 · 11:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Interim results for the six months ended 30 June 2026 | Tue, Sep 15, 2026 · 11:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Preliminary Results | Tue, Mar 24, 2026 · 7:00 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) Q2 2025 Earnings Call | Tue, Sep 16, 2025 · 5:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Full year results for the year ended 31 December 2024 | Tue, Mar 25, 2025 · 12:15 PM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) Q4 2024 Earnings Call | Tue, Mar 25, 2025 · 5:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Interim Results | Wed, Sep 18, 2024 · 11:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Full Year Results | Wed, Mar 20, 2024 · 11:00 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Interim results | Tue, Sep 26, 2023 · 12:30 PM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Preliminary Results | Tue, Mar 28, 2023 · 11:30 AM ET | Replay |
All 13 calls
| Call | When | Status |
|---|---|---|
| EKF Diagnostics Holdings (LSE:EKF) — Half-year Results | Tue, Sep 20, 2022 · 11:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Preliminary Results | Tue, Mar 29, 2022 · 11:30 AM ET | Replay |
| EKF Diagnostics Holdings (LSE:EKF) — Interim results for the six months ended 30 June 2020 | Mon, Sep 14, 2020 · 11:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 15, 2025 · Before open | −1.0% |
| Quarter to Mar 31, 2025 | Apr 24, 2025 | −1.9% |
| Q4 2022 | Mar 28, 2023 · After close | +12.7% |
| Q2 2022 | Sep 20, 2022 · After close | +1.0% |
| Q4 2021 | Mar 29, 2022 · Before open | −13.7% |
| Q2 2021 | Sep 14, 2021 | +3.8% |
| Q4 2020 | Mar 22, 2021 | +3.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 31 slides | Sep 15, 2026 |
| FY2025 Earnings Presentation | Earnings | 37 slides | March 2026 |
| Q2 2025 Earnings Presentation | Earnings | 20 slides | Sep 16, 2025 |
| FY2024 Earnings Presentation | Earnings | 25 slides | Mar 25, 2025 |
| H1 2024 Earnings Presentation | Earnings | 28 slides | September 2024 |
| FY2023 Earnings Presentation | Earnings | 33 slides | 2024 |
| H1 2023 Earnings Presentation | Earnings | 20 slides | September 2023 |
| FY2022 Earnings Presentation | Earnings | 27 slides | March 2023 |
| H1 2022 Earnings Presentation | Earnings | 27 slides | September 2022 |
| FY2021 Earnings Presentation | Earnings | 24 slides | March 2022 |
All 30 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2021 Earnings Presentation | Earnings | 21 slides | Sep 14, 2021 |
| Investor Presentation (June 2021) | Investor deck | 15 slides | Jun 7, 2021 |
| Investor Presentation (April 2021) | Investor deck | 20 slides | April 2021 |
| FY2020 Earnings Presentation | Earnings | 20 slides | Mar 30, 2021 |
| H1 2020 Earnings Presentation | Earnings | 20 slides | Sep 14, 2020 |
| FY2019 Earnings Presentation | Earnings | 15 slides | Mar 24, 2020 |
| H1 2019 Earnings Presentation | Earnings | 22 slides | September 2019 |
| FY2018 Earnings Presentation | Earnings | 24 slides | Mar 13, 2019 |
| Renalytix AI — IPO Roadshow (October 2018) | IPO roadshow | 23 slides | October 2018 |
| H1 2018 Earnings Presentation | Earnings | 9 slides | Sep 19, 2018 |
| FY2017 Earnings Presentation | Earnings | 23 slides | Mar 14, 2018 |
| H1 2017 Earnings Presentation | Earnings | 18 slides | Sep 11, 2017 |
| FY2016 Earnings Presentation | Earnings | 24 slides | Mar 21, 2017 |
| H1 2016 Earnings Presentation | Earnings | 19 slides | Sep 12, 2016 |
| FY2015 Earnings Presentation | Earnings | 29 slides | Apr 12, 2016 |
| Investor Presentation (March 2016) | Investor deck | 31 slides | March 2016 |
| FY2014 Earnings Presentation | Earnings | 35 slides | Mar 16, 2015 |
| H1 2014 Earnings Presentation | Earnings | 32 slides | Sep 15, 2014 |
| FY2013 Earnings Presentation | Earnings | 31 slides | Feb 26, 2014 |
| H1 2013 Earnings Presentation | Earnings | 30 slides | Sep 16, 2013 |
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.6M | 50.2M | 52.6M | 66.6M | 81.8M | 65.3M | 44.9M | 42.5M | 41.6M | 38.6M |
| Cost of revenue | 25.1M | 28.7M | 28.8M | 42.6M | 42.5M | 27.8M | 21.2M | 19.8M | 18.7M | 20.3M |
| Gross profit | 26.5M | 21.5M | 23.9M | 24.0M | 39.4M | 37.4M | 23.7M | 22.7M | 22.9M | 18.3M |
| Research and development | 1.44M | 1.34M | 1.82M | 1.52M | 1.38M | 1.44M | 2.27M | 1.64M | 2.20M | 2.04M |
| Selling, general and administrative | 19.7M | 18.1M | 19.7M | 23.2M | 17.7M | 20.7M | 18.3M | 10.6M | 18.2M | 18.7M |
| Operating income | 6.98M | 6.46M | 2.08M | 7.56M | 21.7M | 16.9M | 5.78M | 12.2M | 4.73M | -327.0K |
| Depreciation and amortization | 5.40M | 4.72M | 5.47M | 6.66M | 5.88M | 4.61M | 4.44M | 3.99M | 4.62M | 4.96M |
| EBITDA | 12.4M | 11.2M | 7.55M | 14.2M | 27.6M | 21.5M | 10.2M | 16.2M | 9.35M | 4.63M |
| Interest expense | 154.0K | 171.0K | 75.0K | 102.0K | 68.0K | 76.0K | 339.0K | 35.0K | 106.0K | 505.0K |
| Income before tax | 7.09M | 6.26M | 2.13M | -8.94M | 21.4M | 15.4M | 5.52M | 12.2M | 4.31M | -1.00M |
| Income tax | 4.55M | -314.0K | -600.0K | 634.0K | 5.28M | 3.97M | 1.59M | 1.87M | 1.37M | -1.17M |
| Net income | 2.12M | 6.24M | 2.35M | -10.1M | 15.9M | 11.1M | 3.68M | 10.1M | 2.71M | -18.0K |
| Earnings per share, basic | 0.00 | 0.01 | 0.01 | -0.02 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | -0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15.8M | 14.3M | 6.02M | 11.6M | 20.3M | 21.9M | 12.1M | 10.3M | 8.20M | 7.87M |
| Short-term investments | -1.29M | |||||||||
| Receivables | 6.04M | 6.28M | 6.23M | 8.59M | 11.7M | 12.7M | 7.62M | 7.14M | 7.12M | 9.16M |
| Inventory | 8.30M | 7.39M | 8.77M | 9.43M | 13.2M | 8.49M | 6.07M | 6.12M | 5.64M | 6.03M |
| Current assets | 30.9M | 28.6M | 25.6M | 31.8M | 47.6M | 44.0M | 26.2M | 23.8M | 21.3M | 23.3M |
| Property, plant and equipment | 21.7M | 17.9M | 13.6M | 13.2M | 12.5M | 12.1M | 12.1M | |||
| Goodwill | 24.1M | 23.9M | 24.4M | 25.1M | 27.4M | 24.4M | 23.8M | 24.9M | 24.4M | 24.8M |
| Total assets | 81.1M | 81.7M | 80.8M | 89.3M | 115.1M | 101.3M | 87.1M | 81.4M | 77.2M | 82.4M |
| Accounts payable | 747.0K | 900.0K | 984.0K | 1.50M | 4.43M | 2.41M | 748.0K | 1.23M | 1.49M | 1.20M |
| Current liabilities | 7.42M | 6.44M | 9.50M | 11.7M | 13.7M | 19.4M | 12.9M | 13.6M | 12.3M | 16.6M |
| Long-term debt | 0 | 0 | 0 | 431.0K | 323.0K | 480.0K | 695.0K | 872.0K | 1.13M | |
| Total debt | 1.39M | 1.32M | 4.10M | 1.55M | 3.47M | 1.96M | 1.66M | 880.0K | 1.21M | 5.72M |
| Total liabilities | 10.9M | 8.53M | 12.6M | 14.8M | 20.4M | 23.1M | 16.0M | 17.5M | 16.7M | 21.5M |
| Shareholders' equity | 69.0M | 72.3M | 67.1M | 73.3M | 94.1M | 77.6M | 70.6M | 63.5M | 60.0M | 60.5M |
| Shares outstanding | 448.5M | 453.7M | 454.1M | 457.2M | 461.0M | 458.8M | 458.4M | 461.5M | 469.3M | 450.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 9.71M | 13.7M | 6.31M | 9.69M | 10.2M | 13.8M | 5.10M | 8.32M | 9.05M | 8.94M |
| Capital spending | -1.53M | -2.25M | -6.97M | -5.83M | -5.65M | -2.65M | -2.38M | -1.85M | -2.21M | -1.92M |
| Free cash flow | 8.18M | 11.4M | -664.0K | 3.86M | 4.59M | 11.2M | 2.73M | 6.47M | 6.84M | 7.02M |
| Cash from investing | -2.34M | -2.66M | -5.64M | -8.93M | -5.48M | 1.34M | -2.40M | -4.93M | -2.03M | -1.43M |
| Cash from financing | -5.86M | -4.08M | -3.65M | -11.0M | -6.16M | -5.21M | -634.0K | -1.49M | -6.42M | -2.11M |
| Dividends paid | -5.45M | -5.46M | -5.10M | -4.55M | -15.0K | -4.55M | -4.55M | |||
| Share buybacks | -4.99M | 0 | 0 | -3.90M | 0 | -7.00K | -15.0K | -940.0K | -241.0K | 4.54M |
| Change in cash | 1.53M | 6.58M | -3.85M | -8.76M | -1.57M | 9.84M | 1.79M | 2.08M | 329.0K | 5.86M |
Cap table
Built by 6ix from EKF Diagnostics Holdings plc’s releases
- Common shares
- 427,968,392
- Fully diluted
- 427,968,392
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 427,968,392 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 427,968,392 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christian Rigg | Senior Independent Non-Executive Director · Since at least Mar 26, 2025 |
| Christopher Mills | Non-Executive Director · Since at least Apr 24, 2026 |
| Gavin Jones | Chief Executive Officer · Since at least Mar 25, 2025 |
| Helen Jones | Chief Financial Officer · Since at least Apr 27, 2026 |
| Jenny Winter | Non-Executive Director · Since at least May 20, 2026 |
| Julian Baines | Executive Chairman · Since at least Jul 30, 2026 |
Log in to ask 6ix AI your own questions about EKF Diagnostics Holdings plc.